Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
Nello Mainolfi, insider at Kymera Therapeutics
Nello Mainolfi Insider Alerts

Get notified the next time Nello Mainolfi buys or sells Kymera Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Nello Mainolfi Insider Information

Nello started his drug discovery career at the Novartis Institutes for Biomedical Research, leading teams to identify multiple novel potential medicines that have entered clinical development across a series of disease areas. Notably he led the team that discovered and developed the first complement factor B inhibitor now in late clinical development across a range of indications. Before founding Kymera, Mainolfi was an Entrepreneur in Residence at Atlas Venture and had previously led discovery research at cancer metabolism startup Raze Therapeutics. Nello has authored >60 papers and patents and has written reviews in the areas of medicinal chemistry, drug discovery and protein degradation. Nello was trained at Imperial College, University of London and The Scripps Research Institute in California.

What is Nello Mainolfi's net worth?

The estimated net worth of Nello Mainolfi is at least $24.34 million as of August 4th, 2021. Dr. Mainolfi owns 457,868 shares of Kymera Therapeutics stock worth more than $24,335,684 as of December 5th. This net worth estimate does not reflect any other assets that Dr. Mainolfi may own. Additionally, Dr. Mainolfi receives a salary of $832,620.00 as CEO at Kymera Therapeutics. Learn More.

How old is Nello Mainolfi?

Dr. Mainolfi is currently 42 years old. There are 4 older executives and no younger executives at Kymera Therapeutics. Learn More.

What is Nello Mainolfi's salary?

As the CEO of Kymera Therapeutics, Inc., Dr. Mainolfi earned a total compensation package of $3,678,001.00 in 2020. Dr. Mainolfi earned a salary of $453,619.00, options awards of $2,845,382.00, non-equity compensation of $379,000.00, and no other miscellaneous compensation.

How do I contact Nello Mainolfi?

The corporate mailing address for Dr. Mainolfi and other Kymera Therapeutics executives is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. Kymera Therapeutics can also be reached via phone at 857-285-5300 and via email at [email protected]

Has Nello Mainolfi been buying or selling shares of Kymera Therapeutics?

Within the last three months, Nello Mainolfi has sold $2,704,596.00 in Kymera Therapeutics stock. Most recently, Nello Mainolfi sold 6,456 shares of the business's stock in a transaction on Monday, October 11th. The shares were sold at an average price of $53.68, for a transaction totalling $346,558.08.

Who are Kymera Therapeutics' active insiders?

Kymera Therapeutics' insider roster includes Bruce Booth (Director), Richard Chesworth (Insider), Bruce Jacobs (CFO), and Nello Mainolfi (CEO).

Are insiders buying or selling shares of Kymera Therapeutics?

In the last twelve months, Kymera Therapeutics insiders bought shares 1 times. They purchased a total of 544,166 shares worth more than $25,575,802.00. In the last twelve months, insiders at the sold shares 32 times. They sold a total of 869,169 shares worth more than $48,659,486.59. The most recent insider tranaction occured on December, 3rd when CFO Bruce N Jacobs sold 10,000 shares worth more than $535,600.00. Insiders at Kymera Therapeutics own 23.3 % of the company.

Information on this page was last updated on 12/3/2021.

Nello Mainolfi Insider Trading History at Kymera Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/11/2021Sell6,456$53.68$346,558.08View SEC Filing Icon  
10/8/2021Sell41,544$56.76$2,358,037.44View SEC Filing Icon  
8/4/2021Sell1,037$60.03$62,251.11457,868View SEC Filing Icon  
8/2/2021Sell23,456$60.30$1,414,396.80452,879View SEC Filing Icon  
7/30/2021Sell6,279$60.07$377,179.53View SEC Filing Icon  
7/28/2021Sell3,864$60.15$232,419.60461,214View SEC Filing Icon  
7/26/2021Sell9,015$60.15$542,252.25461,214View SEC Filing Icon  
7/8/2021Sell48,000$49.70$2,385,600.00500,199View SEC Filing Icon  
6/9/2021Sell5,752$50.02$287,715.04424,923View SEC Filing Icon  
6/7/2021Sell12,724$50.14$637,981.36424,923View SEC Filing Icon  
5/12/2021Sell8,245$50.05$412,662.25405,444View SEC Filing Icon  
4/26/2021Sell2,768$40.18$111,218.24408,158View SEC Filing Icon  
4/23/2021Sell680$40.01$27,206.80408,158View SEC Filing Icon  
4/19/2021Sell653$40.00$26,120.00396,139View SEC Filing Icon  
4/15/2021Sell4,940$40.29$199,032.60396,139View SEC Filing Icon  
4/12/2021Sell15,267$32.62$498,009.54386,138View SEC Filing Icon  
4/9/2021Sell22,794$33.68$767,701.92386,138View SEC Filing Icon  
See Full Table

Nello Mainolfi Buying and Selling Activity at Kymera Therapeutics

This chart shows Nello Mainolfi's buying and selling at Kymera Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kymera Therapeutics Company Overview

Kymera Therapeutics logo
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $53.15
Low: $52.79
High: $55.35

50 Day Range

MA: $59.12
Low: $52.77
High: $65.56

2 Week Range

Now: $53.15
Low: $29.93
High: $91.92

Volume

502,425 shs

Average Volume

222,258 shs

Market Capitalization

$2.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3
Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!